Payment overview · 2025
General Payments
$952.13
55 reported records · 13 companies
Healthcare provider profile · identity verified
William C Hicks, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1235161092
Verified facts
What the public records show
CMS Open Payments records show William C Hicks, M.D received $952.13 in general payments during 2025 across 55 reported records.
Novo Nordisk Inc accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $285.82 | 30.0% | 19 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $173.82 | 18.3% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $145.33 | 15.3% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $78.90 | 8.3% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.23 | 6.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.61 | 4.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.76 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.26 | 3.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.11 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.26 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.86 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.22 | 1.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.95 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $952.13 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $173.82 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $149.72 | 11 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $145.33 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $114.24 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $102.57 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.23 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.29 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.11 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 17 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 124 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1002 | 269 |
| Tramadol Hcl | Tramadol Hcl | 822 | 208 |
| Pantoprazole Sodium | Pantoprazole Sodium | 803 | 255 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 750 | 223 |
| Atorvastatin Calcium | Atorvastatin Calcium | 735 | 215 |
| Montelukast Sodium | Montelukast Sodium | 673 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 475 | 136 |
| Hydralazine Hcl | Hydralazine Hcl | 456 | 133 |
| Losartan Potassium | Losartan Potassium | 409 | 113 |
| Tizanidine Hcl | Tizanidine Hcl | 403 | 143 |
| Fluticasone Propionate | Fluticasone Propionate | 402 | 186 |
| Metformin Hcl | Metformin Hcl | 391 | 116 |
| Allopurinol | Allopurinol | 388 | 112 |
| Meloxicam | Meloxicam | 378 | 118 |
| Gabapentin | Gabapentin | 278 | 90 |
| Trazodone Hcl | Trazodone Hcl | 258 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 80 |
| Potassium Chloride | Potassium Chloride | 241 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 235 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 66 |
| Furosemide | Furosemide | 223 | 73 |
| Lisinopril | Lisinopril | 219 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 200 | 56 |
| Methylprednisolone | Methylprednisolone | 182 | 142 |
| Omeprazole | Omeprazole | 171 | 52 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 170 | 45 |
| Alprazolam | Alprazolam | 167 | 18 |
| Celecoxib | Celecoxib | 167 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 49 |
| Carvedilol | Carvedilol | 161 | 51 |
| Memantine Hcl | Memantine Hcl | 161 | 43 |
| Jardiance | Empagliflozin | 153 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 41 |
| Famotidine | Famotidine | 134 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 42 |
| Eliquis | Apixaban | 124 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 114 | 32 |
| Glimepiride | Glimepiride | 108 | 36 |
| Cefuroxime | Cefuroxime Axetil | 107 | 81 |
| Pregabalin | Pregabalin | 107 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 40 |
| Januvia | Sitagliptin Phosphate | 100 | 28 |
| Meclizine Hcl | Meclizine Hcl | 100 | 44 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 24 |
| Alendronate Sodium | Alendronate Sodium | 95 | 31 |
| Simvastatin | Simvastatin | 94 | 29 |
| Ozempic | Semaglutide | 93 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 61 |
| Ezetimibe | Ezetimibe | 84 | 27 |
| Glipizide | Glipizide | 79 | 22 |
| Sucralfate | Sucralfate | 79 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 58 |
| Clonidine Hcl | Clonidine Hcl | 64 | 22 |
| Telmisartan | Telmisartan | 64 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 16 |
| Colchicine | Colchicine | 61 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 15 |
| Mounjaro | Tirzepatide | 60 | 11 |
| Temazepam | Temazepam | 59 | suppressed |
| Linzess | Linaclotide | 57 | 15 |
| Metformin Hcl Er | Metformin Hcl | 57 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 25 |
| Promethazine Hcl | Promethazine Hcl | 55 | 12 |
| Valacyclovir | Valacyclovir Hcl | 55 | 18 |
| Atenolol | Atenolol | 54 | 14 |
| Levofloxacin | Levofloxacin | 52 | 38 |
| Ketoconazole | Ketoconazole | 50 | 17 |
| Spironolactone | Spironolactone | 50 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 41 |
| Prednisone | Prednisone | 49 | 17 |
| Levetiracetam | Levetiracetam | 48 | 14 |
| Fenofibrate | Fenofibrate | 47 | 14 |
| Fluconazole | Fluconazole | 45 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 15 |
| Xarelto | Rivaroxaban | 44 | 11 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Valsartan | Valsartan | 42 | 12 |
| Azithromycin | Azithromycin | 41 | 33 |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 14 |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 11 |
| Diazepam | Diazepam | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Klor-Con M15 | Potassium Chloride | 32 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 11 |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $952.13 · 55 records | Novo Nordisk Inc | AREXVY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, KISUNLA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, RELISTOR, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error